1. Generics Bulletin
  2. >>Legal & IP

Shot Across The Bow? Express Scripts Lawsuit Aims To Prevent Fall-Out From FTC PBM Report

 
• By Cathy Kelly

Pharmacy benefit manager sues Federal Trade Commission, claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.

Lawsuit May Be Premature Because FTC Has Not Acted Yet

Pharmacy benefit manager Express Scripts Holding Company is seeking a court order “recusing” Federal Trade Commission chair Lina Khan from overseeing further commission action involving the company because she has demonstrated an unfair bias in her approach to investigating the PBM industry.

Key Takeaways

  • Express Scripts lawsuit against the Federal Trade Commission seeks to vacate the commission’s interim report on its PBM investigation and “recuse” chair Lina Khan from participating in further commission action involving its business.

Filed in US district court in eastern Missouri on 17 September, the lawsuit also requests that the interim staff...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

US Court Agrees To Throw Out Viatris Wegovy Infringement Case

 
• By Dean Rudge

Viatris’ Mylan has won a key patent case against Novo Nordisk over generic Wegovy, with a US federal district judge ruling Mylan’s label did not encourage use that infringed Novo’s method-of-treatment patent.

Sun Strikes Further US Price-Fixing Settlement For $200m

 
• By Dave Wallace

The latest development in the long-running US generic price-fixing saga has seen Sun Pharma agree a $200m settlement in connection with an end purchaser action in Pennsylvania.

UK Xtandi Patent Stands Strong As Accord, Sandoz, Teva Lose Appeal

 
• By Dean Rudge

The Court of Appeal in London has upheld a key UK patent shielding Astellas’ Xtandi, rejecting claims by a trio of generic drugmakers that it was obvious after finding that the generics firms’ expert analysis was tainted by hindsight.

US Federal Circuit Clears Path for MSN to Market Entresto Generic

 
• By Dean Rudge

Novartis has failed to secure a court order to stop MSN from launching a generic Entresto, and has also seen an earlier temporary ban lifted, potentially opening the market to competition before a final decision on a US patent dispute.

More from Generics Bulletin

Latest EMA Biosimilar Nods Come For Henlius, Alteogen And Biocon

 
• By Dave Wallace

Denosumab, aflibercept and ustekinumab biosimilars received positive opinions from the EMA’s CHMP at its meeting in July, along with an Opsumit generic from Accord.

Neuraxpharm Targets Asia-Pacific In Latest Phase Of Expansion Beyond Europe

 
• By Dean Rudge

Neuraxpharm has launched its Australian affiliate as part of its continued international expansion beyond Europe. The company will introduce CNS treatments including its acquired Nuvigil, Provigil, and the recently TGA-approved Briumvi for multiple sclerosis.

The Generics Bulletin Top 50, Part Two: Leading Players Leapfrog The Competition

 
• By Dave Wallace

In the second instalment of Generics Bulletin’s Top 50 ranking for 2025, we see plenty of movement among our mid-table collection of companies.